Riskpilot← Back to searchSign inGet full accessORPHAN DIAGNOSTICS AS
ASActiveOrg 918081291Sofies Gate 69, 0168 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20161 employees
Revenue 2024
NOK 479K
+219% vs 2023
EBITDA margin
37.9%
+143% vs 2023
Equity ratio
-423.1%
Financial strength
Net profit 2024
NOK 183K
+143% vs 2023
| Revenue | NOK 479K | +219% |
| EBITDA | NOK 181K | +143% |
| Net profit | NOK 183K | +143% |
| Total assets | NOK 73K | +12% |
| Equity | NOK -307K | +37% |
| Employees | 1 | — |
Legal name
ORPHAN DIAGNOSTICS AS
Org number
918081291
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. november 2016
Share capital
NOK 69 310
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikling, produksjon og salg av medisinsk teknisk utstyr.
Address
Sofies Gate 69, 0168 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 769 | 0 | 80 | 810 | 2 841 | 3 624 | 150 | 479 |
| Staff expenses | −0 | −0 | −0 | −224 | −203 | −330 | −80 | −0 |
| EBITDA | −606 | −199 | 17 | 555 | −1 103 | −887 | −418 | 181 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −606 | −199 | 17 | 555 | −1 103 | −887 | −418 | 181 |
| Net financials | −2 | 0 | 0 | −0 | −14 | −17 | −5 | 1 |
| Profit before tax | −609 | −199 | 17 | 555 | −1 117 | −904 | −423 | 183 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −609 | −199 | 17 | 555 | −1 117 | −904 | −423 | 183 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 168 | 9 | 21 | 856 | 992 | 817 | 65 | 73 |
| Equity | −84 | −283 | −266 | 579 | −538 | −67 | −490 | −307 |
| Long-term debt | 246 | 246 | 246 | 246 | 246 | 246 | 246 | 0 |
| Short-term debt | 6 | 46 | 41 | 30 | 1 284 | 637 | 308 | 380 |
| Total debt | 252 | 292 | 287 | 276 | 1 530 | 884 | 555 | 380 |
EBITDA margin
37.9%
This company
15.8%
Market median
+140% vs market
20172024
Equity ratio
-423.1%
This company
38.2%
Market median
-1208% vs market
20172024
Return on equity
18252000.0%
This company
18.4%
Market median
+99195552% vs market
20172024
Net profit margin
38.1%
This company
8.1%
Market median
+370% vs market
20172024
Asset turnover
6.60×
This company
1.12×
Market median
+489% vs market
20172024
Debt / equity
1.24×
This company
0.62×
Market median
-100% vs market
20172024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2016-10-06 – 2017-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Orphan Medical As | Company | 31.5% | 31.5% | 2022 |
| Individual | 18.6% | 18.6% | 2022 | |
Drubion As | Company | 12.8% | 12.8% | 2022 |
Malsen Medical As | Company | 10.8% | 10.8% | 2022 |
Frihey As | Company | 9.1% | 9.1% | 2022 |
| Individual | 4.7% | 4.7% | 2022 | |
Nemsesk As | Company | 3.9% | 3.9% | 2022 |
Medcon As | Company | 3.2% | 3.2% | 2022 |
| Individual | 2.4% | 2.4% | 2022 | |
| Individual | 1.9% | 1.9% | 2022 | |
| Individual | 1.1% | 1.1% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ORPHAN DIAGNOSTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fridtjof Heyerdahl | Chairman | 0 companies |
| Erik Gill Skaarnæs | Chairman | 0 companies |
| Sigbjørn Olsen | Board of Directors | 0 companies |